NCT02428855

Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research study is studying Dasatinib as a possible treatment for cancer of bile ducts.

Detailed description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied. The standard treatment for metastatic cholangiocarcinoma is combination chemotherapy with gemcitabine and cisplatin. The FDA (the U.S. Food and Drug Administration) has not approved dasatinib for your specific disease (Cholangiocarcinoma) but it has been approved for other uses (Chronic Myeloid Leukemia)

Conditions

• Cholangiocarcinoma

Interventions

Type	Name	Description
DRUG	Dasatinib

Timeline

• Start date: 2015-04-01
• Primary completion: 2018-02-01
• Completion: 2018-02-01
• First posted: 2015-04-29
• Last updated: 2020-07-31
• Results posted: 2020-07-31

Locations

2 sites across 1 country: United States